Sequoia Capital leads $50m Series C in Chinese biotech startup Adagene

Venture capital firm Sequoia Capital China has led the $50-million Series C fundraising round in Adagene, a Chinese antibody discovery and development firm based in Suzhou, according to an announcement.

The latest investment in Adagene, which focuses on the discovery and development of antibody therapeutics for partner companies and for its own internal pipeline, was also participated by New World TMT, AVIC Trust, King Star Capital, and Gopher Asset Management.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter